Oncology Times - OncTimes Talk
136 episodes - English - Latest episode: 14 days ago - ★★★★ - 2 ratingsOncology Times reports essential clinical news for oncologists, hematologists and other cancer care professionals. Learn more about our award-winning journal!
Homepage Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Episodes
The Value of In-Person Meetings
March 01, 2013 22:30 - 14 minutes - 19.8 KBClifford A. Hudis, MD, Chief of the Breast Cancer Medicine Service of Memorial Sloan-Kettering Cancer Center and ASCO’s 2012-2013 President-Elect, explains why face-to-face networking and in-person meetings are important to oncology research, despite faster ways of information sharing. Hear what he told OT Assistant Editor Sarah DiGiulio.
Cancer’s Existential Impact on Survivors
January 23, 2013 23:03 - 3 minutes - 2.86 KBWilliam Breitbart, MD, Acting Chair of the Department of Psychiatry and Behavioral Sciences at Memorial Sloan-Kettering Cancer Center, explains how a cancer experience can change an individual’s sense of meaning and identity—and the psychotherapy intervention programs he developed. Hear his discussion with OT Assistant Editor Sarah DiGiulio.
How Should Physicians Be Paid?
January 21, 2013 18:16 - 9 minutes - 4.36 KBSteven Schroeder, MD, Chairman of the newly formed National Commission on Physician Payment Reform, discusses the commission’s upcoming report on how physicians are paid and what pay incentives mean to patient care—and how oncologists can contribute their thoughts. Hear his chat with OT Contributing Writer and “Practice Matters” blogger Lola Butcher.
Integrating Palliative & Standard Care
November 16, 2012 19:38 - 23 minutes - 10.6 KBThomas J. Smith, MD, Professor of Oncology and Director of Palliative Care at Johns Hopkins Medical Institutions, explains the benefits of making palliative care part of standard oncology care for patients—and the research behind it. Hear Smith’s discussion with OT Contributing Writer and “Practice Matters” blogger Lola Butcher.
The Importance of “Competitive Mortality” in Oncology Care
November 16, 2012 19:35 - 2 minutes - 2.57 KBSteven Tucker, MD, a prostate cancer specialist, discusses “competitive mortality”—how understanding the other conditions in addition to cancer, like chronic disease, old age, and diabetes, that influence a patient’s risk of death improves care overall. Hear Tucker speaking with OT Contributing Writer and “Practice Matters” blogger Lola Butcher. And, read more about the new mortality-index website, ePrognosis, Tucker uses to compare geriatric prognosis indices in the full article.
Will CMS Cast Its Eye Toward Oncology?
September 12, 2012 20:23 - 8 minutes - 4.07 KBReginald Williams II, an Avalere Health Director, discusses his organization’s analysis of how the oncology landscape may be the next topic of scrutiny for the Centers for Medicare & Medicaid Services. Four topics may be ripe for national coverage decisions: lung and prostate cancer screenings, localized prostate cancer treatments, therapies to manage non-small-cell lung cancer, and pharmacogenomic testing for breast and colon cancers. Hear Williams’ discussion with OT Contributing Writer an...
Final Rule for Medicare ACOs
September 12, 2012 20:18 - 2 minutes - 2.31 KBMatt Brow, U.S. Oncology’s top public policy official, breaks down the details of the Medicare Shared Savings Program—the federal government’s final rule on making the accountable care organization model part of Medicare. Brow is the Vice President of Communications in Government and Relations & Public Policy for McKesson Specialty Care Solutions, the parent company of U.S. Oncology.
Multiple Myeloma: Big Survival Gains from Novel Agents 'in the Real World'
August 05, 2010 21:29 - 3 minutes - 906 BytesEvangelos Terpos, speaking at the European Hematology Association 2010 Congress in Barcelona, discusses his group's encouraging findings based on 10 years of experience with thalidomide, lenalidomide, and bortezomib.
From the European Hematology Association 2010 Congress: For Patients with Follicular Lymphoma, Rituximab Maintenance Therapy Cuts Risk of Recurrence in Half (Phase III PRIMA Study)
June 17, 2010 19:27 - 8 minutes - 1.93 KBSpeaking at the meeting in Barcelona, Gilles Salles of the University of Lyon discusses the results showing that patients who had achieved remissions after immunochemotherapy had only half the risk of recurrence if they also received rituximab maintenance therapy for two years compared with patients who did not.
OT Clinical Advisory Editor for Hematology/Oncology Mikkael Sekeres, MD, MS
April 09, 2010 14:52 - 12 minutes - 2.89 KBDr. Sekeres, Director of the Leukemia Program at the Cleveland Clinic Taussig Cancer Institute and Chair of the Hematology/Oncology Pharmacy & Therapeutics Committee, discusses his particular research interests of myelodysplastic syndromes and acute myelogenous leukemia, including the overlaps between the two in older adults, new opportunities to better define MDS epidemiologically in the US, and new treatment approaches.
OT Clinical Advisory Editor for Oncology Ramaswamy Govindan, MD
April 09, 2010 14:49 - 8 minutes - 2.03 KBDr. Govindan, Professor of Medicine and Director of the Thoracic Medical Oncology Program at Washington University Alvin J. Siteman Cancer Center, elaborates on his article in the April 10 issue about the promise and excitement of the new advances in technology that are now making possible a “panoramic view of the rugged genomic landscape of the cancer cell,” transforming cancer research and treatment.
Treatment Recommendations for High- & Low-Risk Early Breast Cancer: New Data from EBCC 7, the European Breast Cancer Conference
April 09, 2010 14:41 - 9 minutes - 2.27 KBLori Pierce on breast-conserving therapy + adjuvant chemotherapy for BRCA 1 & 2 carriers; Annette Heemskerk-Gerritsen on the relationship between contralateral mastectomy & survival; and a recommendation by Ajay Sahu for a "cooling off" period for low-risk patients thinking of having prophylactic contralateral mastectomy.
Pregnancy & Breast Cancer: New Updates from EBCC 7, the European Breast Cancer Conference
April 01, 2010 16:29 - 16 minutes - 3.78 KBHatem Azim on how pregnancy after breast cancer is safe and possibly protective; Angela Ives on why recent -- but not current -- pregnancy worsens breast cancer prognosis; and Sibylle Loibl on how chemotherapy is not generally hazardous to the fetus. Martine Piccart adds commentary & perspective.
Program 4, Day 4, Monday Dec 8
December 09, 2009 02:18 - 22 minutes - 4.89 KBProf Giuseppe Saglio of the University of Turin and San Luigi Gonzaga Hospital in Italy on nilotinib as a new standard of care for chronic myeloid leukaemia. ASH President Nancy Berliner of Brigham & Women's Hospital adds her thoughts. Jorge Cortes of M. D. Anderson Cancer Center on three different ASH papers by his group looking at alternatives to standard imatinib in CML. Jane Apperley of Hammersmith Hospital and Imperial College London, reflects on these, and discusses strategies for dea...
Program 3, Monday Dec 7
December 08, 2009 01:53 - 23 minutes - 4.88 KBGeorge Canellos on aggressive chemotherapy's failure to benefit patients with high-risk B-cell lymphoma. Massimo Martelli of University of Perugia on infused donor T-regulatory cells to prevent graft-vs-host-disease in patients with leukemia & lymphoma; comments from Armand Keating of the University of Toronto. Mathias Rummel of University Hospital in Germany on using bendamustine rather than CHOP combined with rituximab for treating indolent lymphomas—front-line. Commenting: Dr. Canellos ...
Program 1, First Day, Dec. 5
December 07, 2009 18:55 - 16 minutes - 3.91 KBGeorge Canellos: Raising the curtain on ASH 2009. Jorge Cortes, M. D. Anderson Cancer Center, on omacetaxine for CML patients with resistance to imatinib caused by the T 315I mutation; Commentary from Jane Apperley of Imperial College and Dr. Canellos. Srdan Verstovsek, also of M. D. Anderson, on JAK signaling inhibition as a treatment for myelofibrosis; Commentary from Richard Larson of University of Chicago and Dr. Canellos.
Program 2, Sunday Dec. 6
December 07, 2009 02:02 - 19 minutes - 3.91 KBGeorge Canellos, What’s hot from the ASH Plenary Session. Maria-Victoria Mateos of Salamanca University in Spain on melphalan as the better partner drug for bortezomib in multiple myeloma; Commentary Dr. Canellos and Jesus San-Miguel, also of Salamanca, and Richard Van Etten of Tufts University. Steven Devine of Ohio State University on T-cell depletion to avoid GVHD in AML; commentary from Dr. Canellos and Armand Keating of the University of Toronto.
Aromatase Inhibitor Better than Tamoxifen for Initial Adjuvant Therapy for HR- Positive Breast Cancer, But Compliance an Issue!
October 13, 2009 19:01 - 6 minutes - 1000 BytesCornelis van de Velde at ECCO15-ESMO34 on the largest comparison of an aromatase inhibitor with tamoxifen as initial adjuvant therapy for patients with hormone receptor-positive breast cancer--analysis of results from the TEAM (Tamoxifen Exemestane Adjuvant Multinational) study reported at ECCO15-ESMO34.
Longer Follow-up Reveals: Aspirin Prevents Cancer in Lynch Syndrome
October 13, 2009 18:59 - 7 minutes - 1000 BytesJohn Burn talking at ECCO15-ESMO34 in Berlin about his international study showing that aspirin prevented the development of Hereditary Non-Polyposis Colon Cancer in people genetically at risk for the disease.
Swedish Registry Study Shows Hormone Therapy for Prostate Cancer Increased All Cardiovascular Mortality
October 13, 2009 18:57 - 4 minutes - 1016 BytesMieke Van Hemelrijck at ECCO15-ESMO34 on findings that cardiovascular mortality from heart failure and arrhythmia in addition to ischemic heart disease and myocardial infarction increased among patients treated with endocrine therapy—of whatever type—for their prostate cancer.
The Disappointment of the NSABP C-08 Trial
October 13, 2009 18:54 - 9 minutes - 1.95 KBNorman Wolmark on the study's frustrating but unequivocal results showing that bevacizumab did not extend disease-free survival in adjuvant therapy for early colon cancer at 3 years, even though there had been a benefit at 1 year. Also weighing in: Nicholas Petrelli
Research Policy Expert: Overhaul Cancer Research Priorities Globally Now!
October 13, 2009 18:47 - 9 minutes - 1.95 KBRichard Sullivan at ECCO15-ESMO34 on the need for research that is more “trans-national” and funded globally to shift priorities to prevention, surgical innovation and technological development, and creative, “outward branching” thinking. The need, he says, is not just for more investment but for a radical change in thinking and culture.
Advanced Biliary Cancer Controlled with Cetuximab Added to GEMOX
September 02, 2009 01:20 - 2 minutes - 544 BytesÉveline Boucher of Centre Eugene Marquis in France on the encouraging preliminary results of her Phase II open-label study of 101 patients reported at the ESMO World Congress on Gastrointestinal Cancer
Metastatic Colorectal Cancer: Capecitabine Equivalent to 5-FU in Irinotecan/Bevacizumab Combos
September 02, 2009 01:18 - 6 minutes - 1.47 KBMichel Ducreux, Head of the GI Service at Institut Gustave Roussy, talks about the new evidence and its clinical implications, as reported in his Phase II study at the ESMO World Congress on Gastrointestinal Cancer.
Stage IV Pancreatic Islet Cell Tumors: Sunitinib Doubles Progression-Free Survival in Phase III Study
September 02, 2009 01:15 - 4 minutes - 1.06 KBEric Raymond of Beaujon University Hospital in France discusses his study reported at the ESMO World Congress on Gastrointestinal Cancer
NCRI Conference, ASCO Annual Meeting, and Perspectives in Lung Cancer European Congress
July 21, 2009 19:05 - 20 minutes - 18.6 KBNew research for advanced NSCLC showing that combining monoclonal antibodies and chemotherapy can extend life: OTBN Editor Peter Goodwin and Producer Sarah Maxwell talk to Robert Pirker, Christian Manegold, Giorgio Scagliotti, Nick Thatcher, and Howard Sandler, MD. PLUS: Michel Coleman on the latest findings from the CONCORD study of international differences in survival rates for breast, prostate, and colorectal cancers.
ASH Annual Meeting
July 21, 2009 19:02 - 26 minutes - 24.7 KBPeter Goodwin talks to key investigators Francesco Zaja (on rituximab for ITP); Hannes Wandt (on how platelet transfusions may be able to be withheld in certain patients receiving stem cell transplants for hematologic cancers); and Michael Hallek and Tadeusz Robak (on improved benefits for CLL patients with rituximab added to standard chemotherapy). Offering perspective are Kenneth Kaushansky, Linda Burns, and George Canellos.
More from the ASH Annual Meeting!
July 21, 2009 19:00 - 31 minutes - 28.8 KBGreater Role for Umbilical Cord Blood in Adult Transplants (Mary Eapen, commentary from Armand Keating). Ex Vivo Expansion of Cord Blood Derived Progenitor Cells: Patient Transplant Data (Colleen Delaney, commentary from Armand Keating). Erythropoiesis-Stimulating Agents in Cancer Patients: Meta-Analysis Mortality Findings (Julia Bohlius, commentary from Linda Burns and George Canellos). Imatinib: Durable Responses and Survival in CML: 7-Year IRIS Results; Can Imatinib Be Stopped? (Ste...
10th European Congress on Perspectives in Lung Cancer, Brussels
July 21, 2009 18:57 - 7 minutes - 7.08 KBSilvia Novello and Giorgio Scagliotti on harnessing insulin-like growth factor receptor inhibition in a Phase II study that showed clinical activity of figitumumab to be at least as good as that of inhibitors of other growth factors already being used in cancer.
Bilateral Prophylactic Mastectomy for DCIS
July 21, 2009 18:55 - 10 minutes - 9.87 KBTodd Tuttle from University of Minnesota & Abram Recht from Beth Israel Deaconess Medical Center on the surprisingly big recent increase in the use of prophylactic bilateral mastectomy for DCIS.
Cancer-Related Fatigue
July 21, 2009 18:53 - 12 minutes - 11.1 KBPaddy Stone of St. George's Hospital, University of London, & David Cella from Northwestern University Feinberg School of Medicine about the effective use of questionnaires for assessing, screening, and perhaps diagnosing cancer-related fatigue syndrome.
The Smartest Oncologist in the World? – Well, at least in the US!
July 21, 2009 18:43 - 6 minutes - 5.68 KBStanley H. Winokur, MD, on his clever, fun, and ever-evolving one-minute daily Internet quiz that lets oncologists test their knowledge & compete against others. TheSmartestOncologist.com
Breast Cancer: St. Gallen Meeting Endorses Multi-Gene Assays for Refining Chemo Decision
July 21, 2009 18:41 - 7 minutes - 6.65 KBAlso from the Palm Beach Cancer Symposium, Kathy Albain, MD, talks about the St. Gallen consensus meeting’s updated recommendations about adjuvant therapy for breast cancer—i.e., endorsing the 21-gene recurrence score and 70-gene profiling assay as key tools in decision-making for chemotherapy for ER-positive disease.
Oropharyngeal Cancer: Better Outlook with HPV-Directed Therapies
July 21, 2009 18:38 - 6 minutes - 6.12 KBMarshall Posner, MD, talking from Palm Beach Cancer Symposium: Increased prevalence of HPV-related oropharyngeal cancers, more responsive to treatment with induction docetaxel, cisplatin, & 5-FU prior to standard chemoradiotherapy.
CML: Hagop Kantarjian on Treating Patients with the T315I Mutation
July 21, 2009 18:32 - 9 minutes - 8.39 KBAlso: (1) Feasibility of patients becoming pregnant while having TKI treatment after having stable disease for at least two years; and (2) Decreased need for allogeneic transplant.
KRAS-Driven Selection of Molecular Therapy for Metastatic Colorectal Cancer: Choosing Between Bevacizumab, Cetuximab, Panitumomab, or a Combination
July 21, 2009 18:29 - 3 minutes - 3.35 KBInterviewed at the Palm Beach Cancer Symposium, John Macdonald, Chief Medical Officer of Aptium Oncology in Los Angeles, talks about his latest data on the relevance of KRAS tumor status—i.e., whether the gene is wild-type or mutant determines the sensitivity of the tumor to anti-EGF or anti-VEGF receptor therapy. He also discusses the disappointing finding that blocking both of these proliferation pathways does not lead to improved efficacy when two targeted drugs are used in combination.